AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
GAITHERSBURG, Md., April 25, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented preliminary results supporting its Acuitas Rapid Test in development to detect antibiotic resistant genes and the use of predictive algorithms from its Acuitas Lighthouse® Knowledgebase to predict antibiotic susceptibility. The results were presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.
The poster, titled “Prediction of antibiotic resistance in Escherichia coli from resistance genes,” compared phenotypic antibiotic susceptibility testing (AST) with the emerging capabilities of Lighthouse Knowledgebase informatics to predict antibiotic resistance using resistance genes from bacterial isolates. The results of testing over 1,900 E. coli isolates with PCR yielded strong prediction of phenotypic antibiotic resistance for seventeen antibiotics representing seven antibiotic classes with accuracies ranging from 77% to 97%. Resistance for 12 of the antibiotics were predicted with 90% or greater accuracy.
A second poster, titled “Rapid outbreak detection of multidrug-resistant organisms using resistance gene profiles,” illustrated the potential to detect hospital pathogen outbreaks by clustering isolates based on resistance gene profiles using a PCR-based test. Outbreak clusters of P. aeruginosa and E. coli were accurately discriminated using multiple resistance genes, thereby demonstrating that a multiplexed PCR-based test has potential to be a rapid, accurate, and efficient method for surveillance of multidrug-resistant organisms.
“In the preliminary results presented at ECCMID, our Acuitas technology demonstrated the ability to rapidly and accurately predict antibiotic susceptibility using resistance gene profiles,” said Evan Jones, Chairman and CEO of OpGen. “The development of our first Acuitas Rapid Test to detect resistance genes for interpretation by our Acuitas Lighthouse informatics is underway. The data presented at ECCMID support the potential clinical utility of this exciting new technology.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contact: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
